Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Influenza.

N J Cox1, K Subbarao

  • 1Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. njc1@cdc.gov

Lancet (London, England)
|October 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2 primed individuals aged 18-<50 and 50-<70 years old.

The Journal of infection·2024
Same author

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.

The Journal of infection·2024
Same author

Heparin-mediated PCR interference in SARS-CoV-2 assays and subsequent reversal with heparinase I.

Journal of virological methods·2024
Same author

Author Correction: A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts.

Nature cell biology·2023
Same author

A placental model of SARS-CoV-2 infection reveals ACE2-dependent susceptibility and differentiation impairment in syncytiotrophoblasts.

Nature cell biology·2023
Same author

Quantifying the reduction of airborne infectious viral load using a ventilated patient hood.

The Journal of hospital infection·2023
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Same journal

Dual mobility total hip replacement in fractures: stability promotes patient confidence.

Lancet (London, England)·2026
Same journal

Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

Lancet (London, England)·2026
See all related articles

Novel influenza vaccines and antiviral drugs offer new hope for preventing and treating respiratory illness. These advancements, including live attenuated vaccines and neuraminidase inhibitors, promise to improve influenza control and clinical practice.

Area of Science:

  • Virology and Immunology
  • Infectious Diseases
  • Public Health

Background:

  • Influenza remains a significant cause of acute respiratory illness across all age groups.
  • Current influenza prevention relies heavily on inactivated vaccines, primarily for high-risk populations.
  • The persistent burden of influenza necessitates the exploration of innovative control strategies.

Purpose of the Study:

  • To review recent advances in influenza prevention and control.
  • To highlight the development of novel influenza vaccines and antiviral therapies.
  • To discuss the potential impact of these advancements on clinical practice and public health.

Main Methods:

  • Evaluation of an experimental live, attenuated, intranasally administered trivalent influenza vaccine.

Related Experiment Videos

  • Clinical trials assessing new antiviral drugs targeting the neuraminidase molecule.
  • Review of the development of rapid point-of-care diagnostic tests for influenza.

    • Main Results:

    • The intranasal live attenuated influenza vaccine demonstrated high efficacy against influenza A (H3N2) and influenza B in young children.
    • New neuraminidase inhibitor antiviral drugs proved effective against both influenza A and B viruses in clinical trials.
    • The development of rapid diagnostic tests is being accelerated by the anticipated use of new antiviral agents.

    Conclusions:

    • Recent scientific breakthroughs offer promising new tools for influenza management.
    • The integration of new vaccines, antiviral drugs, and diagnostic tests is expected to transform influenza control strategies.
    • These advancements will likely have a substantial impact on clinical practice and patient outcomes.